



## Vaccine Development for Emerging and Zoonotic Diseases

Guest Editor:

### **Dr. Velmurugan Balaraman**

Department of Diagnostic  
Medicine/Pathobiology, College  
of Veterinary Medicine, Kansas  
State University, Manhattan, KS  
66506, USA

Deadline for manuscript  
submissions:

**closed (1 September 2024)**

### **Message from the Guest Editor**

This Special Issue serves as a platform to host original research and comprehensive review articles, all dedicated to the area of emerging and zoonotic animal diseases, with a special focus on vaccine development and the accompanying challenges. The viral disease is not limited to Rift Valley fever virus (RVFV), highly pathogenic avian influenza (HPAI), African swine fever virus (ASFV), and epizootic hemorrhagic disease virus (EHDV). Advancements in vaccine development for zoonotic animal diseases are pivotal, not only for safeguarding animal health but also for enhancing livestock productivity, promoting food security, and mitigating the morbidity and mortality risks associated with potential human and animal diseases.

In this Special Issue, we invite authors to submit original research articles and insightful reviews. Research areas to be explored encompass, but are not limited to, the following:

1. Novel and emerging pathogen detection in animal;
2. Safe and efficacious vaccine approaches to treating Rift Valley fever virus, highly pathogenic avian influenza, African swine fever virus, and epizootic hemorrhagic disease;
3. Vaccine-induced immune responses to animal diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)